Micro Pharmaceuticals
Market Cap
₹835 ₹835 Cr.
P/E
27.77
PEG
1.83
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

Base thesis lives or dies on phase-wise Pen Greenfield conversion into commercial sales, supported by new-market registrations and repeat local order flow for export and domestic supply

Bull path brings Pen lines live early and accelerates export conversion and utilization, pulling the export and local ramp forward

Bear path is triggered by Pen commissioning delays combined with weak export run-rates and collections, soft local offtake, and receivables and borrowing stress

  • Kilitch Drugs(India)
  • Zim Laboratories
  • Anuh Pharma

FAQs on Kilitch Drugs (India) Ltd. Shareprice

Kilitch Drugs(India) has given better returns compared to its competitors.
Kilitch Drugs(India) has grown at ~17.91% over the last 3yrs while peers have grown at a median rate of 5.58%

Kilitch Drugs(India) is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Kilitch Drugs(India) is 25.13, while 3 year average PE is 31.65.
Also latest EV/EBITDA of Kilitch Drugs(India) is 22.8 while 3yr average is 22.58.

Growth Table

  • Kilitch Drugs (India) Ltd.
  • Zim Laboratories
  • Anuh Pharma

Balance Sheet

  • Kilitch Drugs (India) Ltd.
  • Zim Laboratories
  • Anuh Pharma

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Kilitch Drugs (India) Ltd.
  • Zim Laboratories
  • Anuh Pharma

Cash Flow

  • Kilitch Drugs (India) Ltd.
  • Zim Laboratories
  • Anuh Pharma

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Kilitch Drugs (India) Ltd.
  • Zim Laboratories
  • Anuh Pharma

Quarterly Results

  • Kilitch Drugs (India) Ltd.
  • Zim Laboratories
  • Anuh Pharma

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*

FAQs on Kilitch Drugs (India) Ltd. Financials

Balance sheet of Kilitch Drugs(India) is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Kilitch Drugs(India) is increasing.
Latest net debt of Kilitch Drugs(India) is ₹55.19 Crs as of Mar-26.
This is greater than Mar-25 when it was ₹29.78 Crs.

The profit is oscillating.
The profit of Kilitch Drugs(India) is ₹29.2 Crs for TTM, ₹30.17 Crs for Mar 2026 and ₹26.7 Crs for Mar 2025.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Kilitch Drugs(India) latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Capital Work in Progress

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech